Travere Therapeutics Given New 19.00 Price Target at Citigroup

TVTX Stock  USD 18.37  0.10  0.54%   
Slightly above 55% of Travere Therapeutics' investor base is interested to short. The analysis of the overall investor sentiment regarding Travere Therapeutics suggests that many traders are impartial. Travere Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Travere Therapeutics' earnings reports, geopolitical events, and overall market trends.
  
Travere Therapeutics had its price target reduced by Citigroup from 23.00 to 19.00 in a research note published on Friday, Benzinga reports. They currently have a buy rating on the stock. A number of other brokerages also recently weighed in on TVTX. Wedbush boosted their price target on Travere Therapeutics from

Read at thelincolnianonline.com
news
  

Travere Therapeutics Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Travere Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Travere Therapeutics Maximum Pain Price Across March 21st 2025 Option Contracts

Travere Therapeutics' options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Travere Therapeutics close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Travere Therapeutics' options.

Travere Therapeutics Fundamental Analysis

We analyze Travere Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Travere Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Travere Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Total Debt

Total Debt Comparative Analysis

Travere Therapeutics is currently under evaluation in total debt category among its peers. Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.

Travere Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Travere Therapeutics stock to make a market-neutral strategy. Peer analysis of Travere Therapeutics could also be used in its relative valuation, which is a method of valuing Travere Therapeutics by comparing valuation metrics with similar companies.

Peers

Travere Therapeutics Related Equities

VTYXVentyx Biosciences   6.88   
0%
100.0%
MGTXMeiraGTx Holdings   5.56   
0%
80.0%
ANABAnaptysBio   5.46   
0%
79.0%
AKROAkero Therapeutics   4.71   
0%
68.0%
LEGNLegend Biotech   3.91   
0%
56.0%
KROSKeros Therapeutics   3.23   
0%
46.0%
RNAAvidity Biosciences   2.23   
0%
32.0%
RVMDRevolution Medicines   0.98   
0%
14.0%
PTGXProtagonist Therapeutics   0.77   
0%
11.0%
GPCRStructure Therapeutics   0.30   
0%
4.0%
APLSApellis Pharmaceuticals   0.00   
0%
0%
NUVLNuvalent   0.20   
2.0%
0%
STOKStoke Therapeutics   1.06   
15.0%
0%
COGTCogent Biosciences   1.23   
17.0%
0%
IDYAIdeaya Biosciences   2.38   
34.0%
0%
CYTKCytokinetics   2.66   
38.0%
0%
PCVXVaxcyte   2.88   
41.0%
0%

Additional Tools for Travere Stock Analysis

When running Travere Therapeutics' price analysis, check to measure Travere Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Travere Therapeutics is operating at the current time. Most of Travere Therapeutics' value examination focuses on studying past and present price action to predict the probability of Travere Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Travere Therapeutics' price. Additionally, you may evaluate how the addition of Travere Therapeutics to your portfolios can decrease your overall portfolio volatility.